Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 24 (Search time: 0.008 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2003Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCRHui, C.; Goh, K.; White, D.; Branford, S.; Grigg, A.; Seymour, J.; Kwan, Y.; Walsh, S.; Hoyt, R.; Trickett, A.; Rudzki, Z.; Ma, D.; To, L.; Hughes, T.
2007BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteriaBranford, S.; Seymour, J.; Grigg, A.; Arthur, C.; Rudzki, Z.; Lynch, K.; Hughes, T.
2000A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemiaBranford, S.; Rudzi, Z.; Hughes, T.
2003Molecular monitoring of chronic myeloid leukemiaHughes, T.; Branford, S.
2009Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplificationRoss, D.; Schafranek, L.; Hughes, T.; Nicola, M.; Branford, S.; Score, J.
2008Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: Implications for defining sensitivity in minimal residual diseaseRoss, D.; Watkins, D.; Hughes, T.; Branford, S.
2007Monitoring disease responseHughes, T.; Branford, S.
2009Measuring minimal residual disease in chronic myeloid leukemia: Fluorescence in situ hybridization and polymerase chain reactionHughes, T.; Branford, S.
2006Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemiaHughes, T.; Branford, S.
2002High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceBranford, S.; Rudzki, Z.; Walsh, S.; Grigg, A.; Arthur, C.; Taylor, K.; Herrmann, R.; Lynch, K.; Hughes, T.